BNP Paribas Financial Markets’s Protara Therapeutics TARA Stock Holding History

BNP Paribas Financial Markets’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.8K	Sell	7,536 -3,471	-32%	-$16.5K	﹤0.01%	5144
2026 Q1	$57.3K	Buy	11,007 +3,390	+45%	+$20.1K	﹤0.01%	4626
2025 Q4	$40.6K	Sell	7,617 -42,838	-85%	-$238K	﹤0.01%	4780
2025 Q3	$219K	Sell	50,455 -104,210	-67%	-$337K	﹤0.01%	3968
2025 Q2	$469K	Buy	154,665 +2,759	+2%	+$9.52K	﹤0.01%	3363
2025 Q1	$647K	Hold	151,906	–	–	﹤0.01%	3030
2024 Q4	$802K	Buy	+151,906	New	+$491K	﹤0.01%	2965
2016 Q1	–	Sell	-34	Closed	-$21.2K	–	3038
2015 Q4	$21.2K	Sell	34 -4	-11%	-$2.35K	﹤0.01%	3270
2015 Q3	$21.3K	Buy	38 +22	+138%	+$13.6K	﹤0.01%	3285
2015 Q2	$11.4K	Buy	+16	New	+$9.9K	﹤0.01%	3305

Other funds holding TARA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Financial Markets's TARA Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Protara Therapeutics (TARA) stake by 32% in Q2 2026, selling an estimated $16.5K and leaving 7,536 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5144.

BNP Paribas Financial Markets first reported a position in TARA in Q2 2015 and has held it in 10 quarters since. The position peaked at $802K in Q4 2024. 111 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

BNP Paribas Financial Markets held 7,536 shares of Protara Therapeutics worth $28.8K as of Q2 2026.
BNP Paribas Financial Markets sold 3,471 Protara Therapeutics shares in Q2 2026, an estimated $16.5K.
Protara Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5144 holding.
BNP Paribas Financial Markets first reported a position in Protara Therapeutics in Q2 2015 and has held it in 10 quarters since.
BNP Paribas Financial Markets's Protara Therapeutics position peaked at $802K in Q4 2024.
111 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.